CLINICAL EVALUATION OF PANCHATIKTA GHRITA & NALPAMARADI TAILA IN THE MANAGEMENT OF PSORIASIS

Central Council for Research in Ayurvedic Sciences CCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex with age between 18 and 60 years.
•2.Known cases of psoriasis, without psoriatic arthropathy, Exhibiting psoriatic triad â??
•a.Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion.
•b.Under the scales there appears a pinkish moist tender skin.
•c.With the scraping of the moist skin there appear tiny blood droplets (Auspitzâ??s sign)
•3.Patients suffering from psoriasis with less than 50 % of the body surface involvement.
•4.Disease duration between 3 months to 5 years.
•5.V.D.R.L./ HIV/Hepatitis negative.
•6.Positive histopathological finding.(Skin-biopsy)
•7.Willing to participate in the study

•1.Generalized skin lesions, Herpes simplex, Herpes zoster, Scabies, Acne, Urticaria, and Immunological medicated skin diseases like Pempigus vulgaris, Dermatitis,herpetiformis, Guttate, Pustular, Lupus erythematous, Psoriatic arthropathy etc.
•2.Patients with poorly controlled Hypertension (Blood pressure more than 160/100mm of Hg).
•3.Pregnant or lactating women.
•4.Patient with uncontrolled Diabetes Mellitus (Blood sugar fasting more than 250 mg/dl).
•5.Patient suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, cardiovascular disease Tuberculosis, Psycho - Neuro-endocrinal disorders, etc.).
•6.Patients on medication with corticosteroids, phototherapy, biologics,antidepressants any other drugs that may have an influence on the outcome of the study.
•7.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl) oruncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or AIDS or STD or other concurrent severe disease.
•8.Alcoholics and/or drug abusers.
•9.H/o hypersensitivity to the trial drug or any of its ingredients.
•10.Patients who have completed participation in any other clinical trial during the past six months.
•11.Any other condition which the Investigator thinks may jeopardize the study.

发起方

Central Council for Research in Ayurvedic Sciences CCRAS